Rise Advisors’s Prime Medicine PRME Stock Holding History

Rise Advisors’s Portfolio PRME Stock Details PRME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-575	Closed	-$1.14K	–	1622
2025 Q1	$1.14K	Buy	+575	New	+$1.47K	﹤0.01%	1223

Other funds holding PRME

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Rise Advisors's PRME Position: Q2 2025 in Review

Rise Advisors sold out of Prime Medicine (PRME) in Q2 2025, closing a stake of 575 shares — an estimated $1.14K sold.

Rise Advisors first reported a position in PRME in Q1 2025 and held it in 1 quarter. The position peaked at $1.14K in Q1 2025. 121 funds tracked by Wall St. Rank hold PRME as of Q2 2025.

Rise Advisors reported no remaining Prime Medicine position as of Q2 2025 after selling out during the quarter.
Rise Advisors sold 575 Prime Medicine shares in Q2 2025, an estimated $1.14K.
Rise Advisors first reported a position in Prime Medicine in Q1 2025 and held it in 1 quarter.
Rise Advisors's Prime Medicine position peaked at $1.14K in Q1 2025.
121 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2025.

Based on Rise Advisors's 13F filing for Q2 2025, filed 8 Jul 2025.